Sigma-Aldrich has entered into a five-year collaboration to develop optimal cell lines for the production of monoclonal antibodies. Scientists at the University of California, San Francisco will lead the research into antibodies for a variety of cancer targets, autoimmune diseases, stem cell characteristics and commonly neglected disease targets, according to a company statement. Under the terms of the agreement, research targets will be determined by a steering committee composed of leading ...